### Long-term Coexistence of SARS-CoV-2 with Antibody Response

1	<b>Research Article</b>
2	Long-term Coexistence of Severe Acute Respiratory Syndrome
3	Coronavirus 2 (SARS-CoV-2) with Antibody Response in
4	Coronavirus Disease 2019 (COVID-19) Patients
5	
6 7 8	Bin Wang <sup>#,1</sup> , Li Wang <sup>#,1</sup> , Xianggen Kong <sup>1</sup> , Jin Geng <sup>1</sup> , Di Xiao <sup>1</sup> , Chunhong Ma <sup>2</sup> , Xue-Mei Jiang <sup>1,*</sup> & Pei-Hui Wang <sup>2,*</sup>
9 10 11	<sup>1</sup> Jinan Infectious Diseases Hospital of Shandong University, Jinan, Shandong 250021, China <sup>2</sup> Advanced Medical Research Institute, Shandong University, Jinan, Shandong 250012, China
12 13 14 15	<sup>#</sup> These authors contributed equally to this work <sup>*</sup> To whom correspondence should be addressed: Xue-Mei Jiang, <u>shdjxm@163.com</u> ; Pei-Hui Wang, <u>wphlab@163.com</u>
16	

### Long-term Coexistence of SARS-CoV-2 with Antibody Response

# 17 Abstract

18	Severe acute respiratory syndrome coronavirus 2 infection causing coronavirus
19	disease 2019 has spread worldwide. Whether antibodies are important for the adaptive
20	immune responses against SARS-CoV-2 infection needs to be determined. Here, 26
21	cases of COVID-19 in Jinan, China, were examined and shown to be mild or with
22	common clinical symptoms and no cases of severe symptoms were found among
23	these patients. A striking feature of some patients is that SARS-CoV-2 could exist in
24	patients who have virus-specific IgG antibodies for a very long period, with one case
25	for up to 36 days. One COVID-19 patient who did not produce any
26	SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness,
27	revealing that without antibody-mediated adaptive immunity, innate immunity may
28	still be powerful enough to eliminate SARS-CoV-2. Overall, this report may provide a
29	basis for further analysis of both innate and adaptive immunity in SARS-CoV-2
30	clearance, especially in non-severe cases. This study also has implications for
31	understanding the pathogenesis and treatment of SARS-CoV-2.

32

33 Keywords: SARS-CoV-2, COVID-19, adaptive immunity, innate immunity, IgG
34 antibody

# Long-term Coexistence of SARS-CoV-2 with Antibody Response

36	The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
37	outbreak was reported in December 2019, and the virus has rapidly spread worldwide
38	within 3 months (Wu et al., 2020; Zhou et al., 2020; Zhu et al., 2020). The importance
39	of innate and adaptive immunity in the defense against SARS-CoV-1 needs to be
40	urgently determined (Thevarajan et al., 2020). To fulfill the pressing need, we
41	examined antibody generation and virus clearance in 26 patients with SARS-CoV-2
42	caused coronavirus disease 2019 (COVID-19) in Jinan, China.
43	
44	A total of 26 patients from 5 to 72 years old were determined to be SARS-CoV-2
45	RNA positive in sputum, stool, or nasopharyngeal swabs. The clinical characteristics
46	of the patients and chest CT scans were also examined. According to the "Fifth
47	Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment
48	Guidance"
49	( http://www.nhc.gov.cn/yzygj/s7652m/202002/41c3142b38b84ec4a748e60773cf9d4f
50	<u>.shtml</u> ), all of them are non-severe COVID-19 patients (Table 1).
51	
52	Immunoglobulin G (IgG) antibodies act as an indicator of recent and past
53	infection while IgM antibodies indicate current infection. SARS-CoV-2-bound IgG
54	antibodies were detected in the serum of patients. For patients 3, 7, 22 and 24 (Table
55	1), SARS-CoV-2 nucleic acid measurements has become negative before antibodies
56	were detected. Although IgG antibody testing was positive for the first trial in all 4
57	patients, we could not determine the exact role of IgG antibodies in SARS-CoV-2

#### Long-term Coexistence of SARS-CoV-2 with Antibody Response

58	clearance, because innate immunity is also sufficient to eliminate this virus (refer to				
59	the case of patient 26). However, the results did reveals that the antibodies are				
60	produced early and SARS-CoV-2 is cleared up, indicating that the immediate				
61	production of antibodies may contribute to virus clearance.				

62

63 Interestingly, we observed that specimens from patients 2, 13, and 16 who had 64 been confirmed to be IgG antibody positive still tested positive for SARS-CoV-2 65 nucleic acid for more than 30 days (**Table 1**), indicating that SARS-CoV-2 can coexist 66 with its specific antibodies in the human body for an unexpectedly long time (34-36 67 days). According to the data collected from patient 2, IgG antibodies can be produced 68 at least as early as the 7th day post illness. (**Table 1**). The average number of days for 69 SARS-CoV-2 bound IgG antibodies to be firstly detected in the 3 patients was 12.3; 70 thus, the early production of antibodies does not mean early elimination of this virus. 71 The production of specific antibodies is believed to be effective for virus clearance 72 (Jiang, 2020; Lu, 2020), but we could not reach such a conclusion from these cases. 73 We did not observe the a correlation between early adaptive immune responses and 74 better clinical outcomes. Perhaps the specificity and titer of antibodies are more 75 important. To our knowledge, to date, this is the longest period (34-36 days) to 76 observe the coexistence of SARS-CoV-2 with its specific antibodies in COVID-19 77 patients. How this virus can circulate in the presence of specific antibodies for such a 78 long time is an interesting question. Whether SARS-CoV-2 can act as HCV that have 79 developed strategies to subvert humoral immunity and persists in the body is worth

#### Long-term Coexistence of SARS-CoV-2 with Antibody Response

- 80 further investigation (Elsner et al., 2015; Fafi-Kremer et al., 2012; Takaya et al.,
  81 2019).
- 82
- These 3 patients were all 23-39 year-old adults, which may suggest that young adult individuals do not have obvious advantages in the early production of antibodies and the clearance of SARS-CoV-2 compared to older persons (patients 10 and 21).
- 86

87 We observed that patient 26, a 5-10 year-old female, was SARS-CoV-2 nucleic 88 acid positive in a stool sample after 46 days of illness but became nucleic acid testing 89 negative in specimens of sputum, stool, and nasopharyngeal swabs on day 47 post 90 illness (**Table 1**). No SARS-CoV-2–specific antibodies were detected in the patient's 91 serum until the latest sample collection day, which was the 66th day post illness. 92 Although we did not collect data about virus-specific cellular immunity, it is known 93 that cellular immunity is generated concomitantly with humoral immunity, so we 94 could preliminarily exclude the potential role of cellular immunity in SARS-CoV-2 95 elimination in this case. Thus, from the data on patient 26, we may conclude that 96 innate immunity, the first line of host defense, can play an essential role in 97 SARS-CoV-2 clearance; moreover, innate immunity alone might be enough to clear 98 the virus. This case may also indicate that some individuals may not generate specific 99 antibodies after infection with SARS-CoV-2; thus, only testing SARS-CoV-2-specific 100 antibodies is not a good standard to determine infection, but combination with the 101 nucleic acid testing method may improve the accuracy of SARS-CoV-2 detection.

# Long-term Coexistence of SARS-CoV-2 with Antibody Response

103	Patient 25, another 5-10 year-old female, was found to be IgG antibody positive
104	on the 10th day post illness, and the patient turned SARS-CoV-2 nucleic acid negative
105	on 23rd day post illness (Table 1). We also observed that a 5-10 year-old female
106	patient (patient 7) produced IgG antibodies on the 14th day post illness, and this
107	patient turned SARS-CoV-2 nucleic acid negative on the 28th day post illness (Table
108	1). These 2 cases may reveal that children do not show any defects in antibody
109	production and SARS-CoV-2 elimination compared with adults.
110	
111	Although a vaccine is believed to be the ultimate preventive measure against
112	SARS-CoV-2 spread, generating a broadly protective and universal vaccine can take a
113	long time (Lu, 2020). In this study, in the case of patient 26 (Table 1), we observed
114	that innate immunity alone may be enough to completely clear SARS-CoV-2 infection.
115	This is the first report that innate immunity plays such an essential role in the host
116	defense against SARS-CoV-2, which highlights the importance of innate immunity in
117	SARS-CoV-2 clearance. Further studies are required to determine which factors or
118	signaling pathways of innate immunity contribute to this process. Whether individuals
119	with such responses are still at risk for reinfection needs further exploration. Similar
120	to other RNA viruses, SARS-CoV-2 RNA should be detected by endosomal Toll-like
121	receptors (TLRs) and cytosolic RIG-I-like receptors or other RNA sensors that
122	activate NLRP3 signaling, leading to the production of IFNs, ISGs, and
123	proinflammatory cytokines (Kasumba and Grandvaux, 2019). Boosting innate

#### Long-term Coexistence of SARS-CoV-2 with Antibody Response

124	immune signaling pathways, such as TLR3 and RIG-I pathways, by drugs that mimic
125	viral RNA may contribute to SARS-CoV-2 clearance (Kasumba and Grandvaux,
126	2019). However, these immune stimulators also induce an inflammatory response that
127	may be harmful to patients, thus, antiviral immunity should be maximized, and
128	inflammatory responses must be minimized. The inflammatory response that is
129	responsible for the accumulation of cells and fluids contributes to SARS induced
130	lung injury (Huang et al., 2020; Wang et al., 2020). As immune stimulators, viral
131	RNA mimics also induce an inflammatory response that may be harmful to patients;
132	thus a strategy in which antiviral immunity should be maximized and inflammatory
133	responses must be minimized, is challenging. Vaccine combined with innate immune
134	stimulators may be more effective for fast SARS-CoV-2 clearance. We propose that
135	the importance of innate immunity should be investigated further and that the titer and
136	specificity of SARS-CoV-2-specific antibodies are important and should be seriously
137	considered in vaccine development.

138

Our study is limited by the current reagents used in this study, which cannot be used to determine the titer and specificity of human antibodies against SARS-CoV-2. The titer of specific antibodies correlated with clinical outcomes remains to be investigated. The long-term coexistence of IgG antibody with SARS-CoV-2 in the human body raises the question of whether patients with antibodies are still at risk for reinfection. Our follow-up studies may answer this question and would, therefore, be beneficial to vaccine development. Second, we did not collect the earliest serum of

# Long-term Coexistence of SARS-CoV-2 with Antibody Response

146	patients, and we could not determine on which day the SARS-CoV-2 bound IgG
147	antibodies generated. Thus, we could not observe the dynamic changes in IgG
148	antibodies during illness and recovery. Third, we lack severe patients as controls;
149	therefore, we do not know whether the adaptive immunity of severe patients can
150	respond earlier because of their strong immune response and whether they can clear
151	the virus faster after antibodies are produced. Despite that, our study provided several
152	novel pieces of information about the innate and adaptive immune response against
153	SARS-CoV-2: IgG antibodies can be generated as early as 7 days post illness but can
154	coexist with SARS-CoV-2 in patients long-term; without IgG antibodies, innate
155	immunity can also successfully clear SARS-CoV-2.
156	

# Long-term Coexistence of SARS-CoV-2 with Antibody Response

# 158 Materials and Methods

159	Specimens from sputum, stool, and nasopharyngeal swabs were collected
160	throughout the illness from January 30, 2020, to March 19, 2020. Viral RNA was
161	extracted from clinical specimens and real-time reverse transcription-PCR (rRT-PCR)
162	was performed to test the presence of SARS-CoV-2 using "Novel coronavirus
163	2019-nCoV nucleic acid detection kit" (Shanghai BioGerm Medical Biotechnology
164	Co.,Ltd, China). The serum was collected at distinctive time points, and
165	SARS-CoV-2-specific antibodies were detected using "New Coronavirus
166	(2019-nCoV) Antibody Detection Kit'' (INNOVITA, China). This study was approved
167	by the ethics commissions of Jinan infectious disease hospital, Shandong, China.
168	

## Long-term Coexistence of SARS-CoV-2 with Antibody Response

# 169 Acknowledgement

- 170 This work was supported by grants from COVID-19 emergency tackling research
- 171 project of Shandong University (Grant No. 2020XGB03 to P.-H.W).

#### Long-term Coexistence of SARS-CoV-2 with Antibody Response

#### 173 **References**

- 174 Elsner, R.A., Hastey, C.J., Olsen, K.J., and Baumgarth, N. (2015). Suppression of
- 175 Long-Lived Humoral Immunity Following Borrelia burgdorferi Infection. PLoS
- 176 Pathog *11*, e1004976.
- 177 Fafi-Kremer, S., Fauvelle, C., Felmlee, D.J., Zeisel, M.B., Lepiller, Q., Fofana, I.,
- 178 Heydmann, L., Stoll-Keller, F., and Baumert, T.F. (2012). Neutralizing antibodies
- and pathogenesis of hepatitis C virus infection. Viruses *4*, 2016-2030.
- 180 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu,
- 181 X., *et al.* (2020). Clinical features of patients infected with 2019 novel
  182 coronavirus in Wuhan, China. Lancet *395*, 497-506.
- Jiang, S. (2020). Don't rush to deploy COVID-19 vaccines and drugs without
  sufficient safety guarantees. Nature *579*, 321.
- 185 Kasumba, D.M., and Grandvaux, N. (2019). Therapeutic Targeting of RIG-I and

186 MDA5 Might Not Lead to the Same Rome. Trends Pharmacol Sci 40, 116-127.

- 187 Lu, S. (2020). Timely development of vaccines against SARS-CoV-2. Emerg
- 188 Microbes Infect *9*, 542-544.
- Takaya, A., Yamamoto, T., and Tokoyoda, K. (2019). Humoral Immunity vs.
  Salmonella. Front Immunol *10*, 3155.
- 191 Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E.,
- 192 Jia, X., Nicholson, S., Catton, M., Cowie, B., et al. (2020). Breadth of
- 193 concomitant immune responses prior to patient recovery: a case report of
- 194 non-severe COVID-19. Nature Medicine.

#### Long-term Coexistence of SARS-CoV-2 with Antibody Response

- 195 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z.,
- 196 Xiong, Y., et al. (2020). Clinical Characteristics of 138 Hospitalized Patients
- 197 With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
- 198 Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian,
- 199 J.H., Pei, Y.Y., et al. (2020). A new coronavirus associated with human
- 200 respiratory disease in China. Nature.
- 201 Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li,
- B., Huang, C.L., *et al.* (2020). A pneumonia outbreak associated with a new
  coronavirus of probable bat origin. Nature.
- 204 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W.,
- Lu, R., et al. (2020). A Novel Coronavirus from Patients with Pneumonia in
- 206 China, 2019. N Engl J Med *382*, 727-733.
- 207

#### Long-term Coexistence of SARS-CoV-2 with Antibody Response

### 209 Table 1 Clinical characteristics of the 26 hospitalized SARS-CoV-2 patients and

Patients	Gender/Age (Y.)	Туре	IgG P. (D.)	LDVP/specimens	Co-existence (D.)
1	F/18-60	С	22	22/NP	0
2	M/18-60	С	7	42/SP	35
3	F/18-60	С	23	18/NP	NA
4	F/18-60	С	16	32/ST	16
5	F/18-60	С	23	29/NP	6
6	F/18-60	С	21	21/ST	0
7	F/18-60	М	9	8/NP	NA
8	M/18-60	С	23	43/NP	20
9	M/18-60	С	10	23/NP	13
10	M/>60	С	9	19/SP&NP	10
11	M/18-60	С	17	20/NP	3
12	F/<18	М	14	28/ST	14
13	M/18-60	С	15	51/ST	36
14	F/18-60	С	10	25/SP	24
15	M/18-60	С	24	36/NP	12
16	F/18-60	С	15	49/NP	34
17	M/18-60	С	20	36/SP	16
18	M/18-60	М	17	24/NP	7
19	M/18-60	С	12	21/SP	9
20	F/18-60	С	18	20/NP	2
21	F/>60	С	14	20/NP	6
22	M/18-60	М	10	7/NP	NA
23	F/18-60	С	15	18/NP	3
24	F/18-60	С	18	17/NP	NA
25	F/<18	С	10	23/ST	13
26	F/<18	М	ND* ( 66 <sup>th</sup> )	46/ST	NA

### 210 corresponding timelines of IgG antibody production.

211

Y: year; IgG P: IgG positive; LDVP: Last day post-illness when SARS-CoV-2 212 213 nucleic acid testing shows positive; NP: nasopharyngeal; SP: sputum; ST: stool. The 214 severity of COVID-19 was judged according to the "Fifth Revised Trial Version of the 215 Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance". M: mild type, 216 the clinical symptoms were mild and no pneumonia was found in imaging. C: 217 common type, with fever, respiratory tract and other symptoms, the manifestations of 218 pneumonia can be seen on imaging. NA: not applicable; ND: not detectable. \* IgG 219 antibodies keep undetectable till 66th day post-illness for patient 26.

220